Office for Technology Commercialization
http://www.research.umn.edu/techcomm
612-624-0550

Mammalian Cell Culture System for Anaplasmosis Vaccine Development

Technology #z02209

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
Anaplasmosis AntigenAnaplasma phagocytophiliumAnaplasma
Categories
Researchers
Ulrike Munderloh, PhD
Associate Professor, Department of Entomology, College of Food, Agricultural and Natural Resource Sciences
External Link (www.entomology.umn.edu)
Managed By
Raj Udupa
Technology Licensing Officer 612-624-3966
Patent Protection
US Patent 7,361,504

Anaplasma phagocytophilium

Anaplasmosis is a disease caused by Anaplasma phagocytophilium. This intracellular bacterium is transmitted via infected tick bites, and infects humans and animals in North America, Europe, Australia, and Africa. A method of propagating Anaplasma species stably in mammalian cells would assist both industry and academia research and development.

Culturing Anaplasma for Antigen Use

A way to propagate Anaplasma species in mammalian cells has been developed at the University of Minnesota. An Anaplasma species stably infects a mammalian endothelial cell, which is propagated then isolated. This culturing system allows for genetic analysis and provides a source of Anaplasma for use as an antigen for potential anaplasmosis diagnostics or treatments.

MN-IP Try and Buy
This research method is immediately available for a nonexclusive license. Contact Raj Udupa for specific details.

BENEFITS AND FEATURES OF CELL LINES FOR PROPAGATING ANAPLASMA:

  • Provides cells that are stably infected with Anaplasma species
  • Allows for propagation of Anaplasma species in mammalian cells for at least 8 weeks
  • Isolation of Anaplasma species for research use

Fulfillment Details

Licensee will receive rights to practice the intellectual property (Patent) for the purposes of developing and manufacturing a commercial product.

Phase of Development

In Vitro Assessment